https://clinicaltrials.gov/ct2/show/NCT03782636
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD) (ITAD)
Study Type : Interventional
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
Actual Study Start Date : January 28, 2019
Estimated Primary Completion Date : April 14, 2022
Estimated Study Completion Date : April 14, 2022
